Skip to main content
. 2019 Dec 30;24(2):157–166. doi: 10.1007/s10157-019-01810-w

Table 4.

Adverse events in the Japanese patients randomly assigned to the migalastat group (n = 5)

Month 0–30 (ATTRACT) After month 30 (AT1001-042 OLE study)
Number of AEs 34 15
Number of patients who experienced AEs, n (%) 5 (100.0) 4 (80.0)
The most frequently reported AEs (reported in 2 or more Japanese patients), n (%)
Nasopharyngitis 4 (80.0) 2 (40.0)

AE adverse event, OLE open-label extension